Cantor Fitzgerald Reiterates Overweight on Intra-Cellular Therapies, Maintains $120 Price Target
BenzingaApr 24 09:57 ET
Analysts Offer Insights on Healthcare Companies: BioLife Solutions (BLFS) and Intra-Cellular Therapies (ITCI)
TipRanksApr 24 08:50 ET
Intra-Cellular Therapies Analyst Ratings
BenzingaApr 23 10:48 ET
Buy Rating on Intra-Cellular Therapies as Caplyta Shows Promise in Major Depressive Disorder Market
TipRanksApr 22 10:05 ET
Intra-Cellular Therapies Analyst Ratings
BenzingaApr 22 07:10 ET
Analysts Are Bullish on Top Healthcare Stocks: Thermo Fisher (TMO), Intra-Cellular Therapies (ITCI)
TipRanksApr 18 21:50 ET
Analysts Conflicted on These Healthcare Names: Intra-Cellular Therapies (ITCI), Eli Lilly & Co (LLY) and Sanofi (OtherSNYNF)
TipRanksApr 18 08:20 ET
Intra-Cellular Therapies Analyst Ratings
BenzingaApr 17 06:14 ET
Analysts Offer Insights on Healthcare Companies: Johnson & Johnson (JNJ) and Intra-Cellular Therapies (ITCI)
TipRanksApr 17 05:20 ET
Intra-Cellular Therapies: Hold Rating With Increased Price Target Amid Caplyta's Clinical Success
TipRanksApr 16 15:45 ET
Analysts Offer Insights on Healthcare Companies: Ultragenyx Pharmaceutical (RARE) and Intra-Cellular Therapies (ITCI)
TipRanksApr 16 08:11 ET
Analysts Offer Insights on Healthcare Companies: Cardiol Therapeutics (CRDL), Paragon 28 (FNA) and Intra-Cellular Therapies (ITCI)
TipRanksApr 5 07:00 ET
Intra-Cellular Therapies Buy Rating: High Confidence in Caplyta's Success for MDD Treatment
TipRanksApr 5 05:25 ET
Intra-Cellular Therapies Analyst Ratings
BenzingaApr 5 05:13 ET
Intra-Cellular Therapies Analyst Ratings
BenzingaApr 3 08:48 ET
Analysts' Top Healthcare Picks: Amgen (AMGN), Intra-Cellular Therapies (ITCI)
TipRanksApr 3 07:00 ET
Buy Rating Affirmed on Intra-Cellular Therapies Ahead of Key Phase 3 Results and Strategic Leadership Enhancements
TipRanksMar 21 02:45 ET
Buy Rating Affirmed for Intra-Cellular Therapies Amid Positive Outlook for Caplyta's MDD Trial
TipRanksMar 5 01:26 ET
Outperform Rating for Intra-Cellular Therapies Amidst Strong Caplyta Sales and Promising Clinical Prospects
TipRanksMar 1 01:13 ET
Optimistic Buy Rating for Intra-Cellular Therapies Amid Growth and Operational Efficiency
TipRanksFeb 25 23:56 ET
No Data
No Data